Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products for intravenous administration

BMC Clinical Pharmacology

Volumn 10, Issue , 2010, Pages

  Silva, Edelberto ^a   Díaz, Jorge A ^a   Arias, María J ^a   Hernández, Angela P ^a   de la Torre, Andrés ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE; DRUG DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; TAZOBACTAM; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS SUBTILIS; BACTERIAL STRAIN; BACTERIUM MUTANT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS GALLINARUM; ESCHERICHIA COLI; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA PNEUMONIAE; MICROCOCCUS LUTEUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; ANIMAL; BACTERIUM; BAGG ALBINO MOUSE; CAMPYLOBACTERIOSIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; MOUSE; MULTIDRUG RESISTANCE; TISSUE DISTRIBUTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAMASES; CAMPYLOBACTER INFECTIONS; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; PENICILLANIC ACID; PIPERACILLIN; THIENAMYCINS; TISSUE DISTRIBUTION;

EID: 77649090002     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-10-3     Document Type: Article

References (11)

1. World Health Organization Communicable Disease Surveillance and Response Containing. Antimicrobial Resistance: Review of the Literature and Report of a WHO Workshop on the Development of a Global Strategy for the Containment of Antimicrobial Resistance. Geneva, Switzerland 1999, World Health Organization.
2. Centers for disease control and prevention, food and drug administration, national institutes of health A Public Health Action Plan to Combat Antimicrobial Resistance. Centers for disease control and prevention, food and drug administration, national institutes of health., http://www.cdc.gov/drugresistance/actionplan/index.htm
3. Jones RN, Fritsche TR, Moet GJ. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn®, Wyeth) formulation. Diagnostic Microbiology and Infectious Disease 2008, 61:76-79. 10.1016/j.diagmicrobio.2007.12.010, 18221852.
4. Rodriguez CA, Zuluaga AF, Salazar BE, Agudelo M, Vesga O. Experimental comparison of 11 generic products (GP) of oxacillin (OXA) with the original compound (OC) in terms of concentration of active principle (CAP), in vitro activity, and in vivo efficacy, using the neutropenic murine thigh infection model (NMTIM). Abstr. A-1305. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D.C 2004, 28.
5. Zuluaga AF, Salazar BE, Loaiza SA, Agudelo M, Vesga O. Therapeutic equivalence (TE) with the original compound (OC) of 8 genetic products (GP) of Ampicillin (AMP) determined in the neutropenic murine thigh infection model (NMTIM). Abstr. E- 203344th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D.C 2004,
6. Melendez P, Diaz J, Silva E, Gonzales P, Gonzalez P, Moreno E, Amaya P, Serrato N, Saenz E. Estudio comparativo de la actividad antimicrobiana de diferentes presentaciones comerciales de antibióticos de administración intravenosa a través de métodos in Vitro. Revista Colombiana de Ciencias Químico-Farmacéuticas 2005, 34.
7. Victor L, . Ed Antibiotics in Laboratory Medicine. Williams & Wilkins. Baltimore 1980, 95-98. Ed.
8. Hewitt, William. Microbiological assay - An introduction to Quantitative Principles and Evaluation. 1977, 17-42. Academic Press. New York.
9. The United States Pharmacopoeia. XXVII Biological test and assays. 1883, 358. Ed Pharmacopoeia Convention Inc Bronx New York USA, The United States Pharmacopoeia. XXVII.
10. Mendez ASL, Weisheimer V, Oppe TP, Steppe M, Schapoval E. Microbiological assay for the determination of meropenem in pharmaceutical dosage form. Journal of Pharmaceutical and Biomedical Analysis 2005, 37:649-653. 10.1016/j.jpba.2004.11.030, 15797784.
11. Zuluaga AF, Agudelo M, Rodriguez CA, Vesga O. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. BMC Clinical Pharmacology 2009, 9:1. 10.1186/1472-6904-9-1, 2640365, 19149891.